Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 3/20 | 0.41 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | FASN | P49327 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716836 | 0.88 | HRH3 (0.45) | CXCR4MAPTCYP2C9NPSR1SYK | |
| SCHEMBL91452 | 0.83 | NPSR1 (0.46) | MAPTCYP2C9NPSR1MAPK1SMN1; SMN2 | |
| SCHEMBL10225045 | 0.81 | MAPK1 (0.59) | MAPTCYP2C9NPSR1MAPK1SMN1; SMN2 | |
| SCHEMBL11399621 | 0.80 | NPSR1 (0.44) | MAPTCYP2C9NPSR1MAPK1SMN1; SMN2 | |
| SCHEMBL13403107 | 0.80 | HRH4 (0.56) | MAPTCYP2C9NPSR1MAPK1SMN1; SMN2 | |
| SCHEMBL7204411 | 0.79 | CXCR4 (0.55) | CXCR4SYKZAP70FERMT2ALDH1A1 | |
| SCHEMBL38657414 | 0.79 | DNM2 (0.57) | MAPTCYP2C9NPSR1 | |
| SCHEMBL91582 | 0.79 | MKNK1 (0.51) | MAPTCYP2C9NPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL13034550 | 0.79 | DNM2 (0.57) | MAPTCYP2C9NPSR1 | |
| SCHEMBL13218581 | 0.79 | HRH4 (0.43) | MAPTCYP2C9NPSR1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486950-B2 | Janus kinase inhibitor compounds and methods | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-16 | — | — | US | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | CXCR4 1378/4885MAPT 2745/4885CYP2C9 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.